CYP19A1

Aromatase · P11511 · CYP19A1 on Sugi Atlas →

475,286 patent compounds predicted against CYP19A1, 266,379 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Plomestane (SCHEMBL3434)	1.00	20/20
Letrozole (SCHEMBL4331)	1.00	20/20
Vorozole (SCHEMBL4554)	1.00	20/20
Rogletimide (SCHEMBL4281)	1.00	19/20
Aminoglutethimide (SCHEMBL4306)	1.00	19/20
Anastrozole (SCHEMBL9726)	1.00	19/20
Exemestane (SCHEMBL6215)	1.00	18/20
Androstenedione (SCHEMBL23272)	1.00	18/20
Nimesulide (SCHEMBL24882)	1.00	18/20
Androstenedione (SCHEMBL27901)	1.00	18/20
SCHEMBL42712	1.00	18/20
SCHEMBL42713	1.00	18/20
SCHEMBL8506	0.69	18/20
Fenarimol (SCHEMBL42209)	1.00	17/20
Nuarimol (SCHEMBL20691)	0.78	17/20
Formestane (SCHEMBL25717)	0.74	17/20
Levoketoconazole (SCHEMBL8407)	1.00	16/20
Ketoconazole (SCHEMBL8408)	1.00	16/20
Levoketoconazole (SCHEMBL41473)	1.00	16/20
Testolactone (SCHEMBL4053)	1.00	15/20

Clinical trials — most relevant to CYP19A1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF	PHASE4	COMPLETED
Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial	PHASE4	COMPLETED
Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)	PHASE3	COMPLETED
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors	PHASE3	UNKNOWN
Letrozole After Tamoxifen in Treating Women With Breast Cancer	PHASE3	COMPLETED
Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer	PHASE2	COMPLETED
A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia	PHASE1/PHASE2	NOT_YET_RECRUITING
Letrozole for Lymphangioleiomyomatosis	PHASE2	COMPLETED
Effectiveness of Pretreatment Letrozole Versus Misoprostol Alone in Missed Abortion	PHASE2	UNKNOWN
Anastrozole in Treating Postmenopausal Women With DCIS or Stage I-III Breast Cancer	PHASE2	COMPLETED
Goserelin/Letrozole in Premenopausal Patients vs Letrozole Alone in Postmenopausal Patients With MBC	PHASE2	COMPLETED
Reciprocal Influence of Sex Steroid Environment and Adipocyte Function in Men	PHASE1/PHASE2	COMPLETED
Effect of Vitamin D Supplementation on Testosterone Level in Women With Polycystic Ovary Syndrome	PHASE2	COMPLETED
Letrozole Treatment in Normal and GnRH Deficient Women	PHASE1/PHASE2	UNKNOWN
AMG 386 and Abiraterone for Advanced Prostate Cancer	PHASE2	COMPLETED
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy	PHASE1	COMPLETED
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency	PHASE1	COMPLETED
Impact of Endogenous E2 on SSI and GH Rebound	PHASE1	COMPLETED
Cost Effectiveness Analysis for Induction of Ovulation in the Polycystic Ovary Syndrome by Letrozole Versus Clomiphene Citrate	EARLY_PHASE1	UNKNOWN
Aromatase Inhibitor Clinical Trial	nan	UNKNOWN
Aromatase Inhibitor Host Factors Study	nan	COMPLETED
Effect of Aromatase Inhibitors on Bones and Genes	nan	COMPLETED
Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer	nan	COMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN
S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer	nan	COMPLETED
Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction	nan	COMPLETED
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Meal Timing on Glucose and Hyperandrogenism in PCOS Women	nan	UNKNOWN
Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer	nan	COMPLETED
Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CYP19A1 binder may also engage these)

Protein	Name	Similarity
Q6YI21	—	1.000	Q6YI21 →
P28649	—	1.000	P28649 →
Q95M61	—	1.000	Q95M61 →
Q5QQX7	—	1.000	Q5QQX7 →
P79304	—	1.000	P79304 →
O46512	—	1.000	O46512 →
P79430	—	1.000	P79430 →
Q9XS28	—	1.000	Q9XS28 →
P46194	—	1.000	P46194 →
P19098	—	1.000	P19098 →
Q29624	—	1.000	Q29624 →
Q29605	—	1.000	Q29605 →
Q92112	—	1.000	Q92112 →
Q69FB6	—	1.000	Q69FB6 →
P70091	—	1.000	P70091 →
P22443	—	1.000	P22443 →
P79690	—	1.000	P79690 →
Q6QHT9	—	1.000	Q6QHT9 →
Q92087	—	0.999	Q92087 →
O42145	—	0.998	O42145 →
O73686	—	0.996	O73686 →
P79699	—	0.995	P79699 →
A0A386KZI3	—	0.992	A0A386KZI3 →
Q92111	—	0.992	Q92111 →
A0A1U8QFC3	—	0.992	A0A1U8QFC3 →
Q1ZXF5	—	0.991	Q1ZXF5 →
B9DFU2	—	0.991	B9DFU2 →
A0A0G2RKY1	—	0.990	A0A0G2RKY1 →
Q5UQI3	—	0.990	Q5UQI3 →
A0A1U9YI05	—	0.989	A0A1U9YI05 →